Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication

Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H....

Full description

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 16; no. 3; pp. 527 - 532
Main Authors Di Caro, S., Ojetti, V., Zocco, M. A., Cremonini, F., Bartolozzi, F., Candelli, M., Lupascu, A., Nista, E. C., Cammarota, G., Gasbarrini, A.
Format Journal Article
LanguageEnglish
Published Oxford UK Blackwell Science Ltd 01.03.2002
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H. pylori‐positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention‐to‐treat and per protocol analyses were performed. Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Conclusions: Mono and dual moxifloxacin‐based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin‐based triple therapy may be considered as a new, effective, first‐line therapy option.
AbstractList Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H. pylori‐positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention‐to‐treat and per protocol analyses were performed. Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Conclusions: Mono and dual moxifloxacin‐based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin‐based triple therapy may be considered as a new, effective, first‐line therapy option.
Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. To compare the efficacy of different 1-week moxifloxacin-based Helicobacter pylori eradication regimens. One hundred and twenty H. pylori-positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention-to-treat and per protocol analyses were performed. One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Mono and dual moxifloxacin-based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin-based triple therapy may be considered as a new, effective, first-line therapy option.
Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H. pylori ‐positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention‐to‐treat and per protocol analyses were performed. Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Conclusions: Mono and dual moxifloxacin‐based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin‐based triple therapy may be considered as a new, effective, first‐line therapy option.
Author Candelli, M.
Zocco, M. A.
Di Caro, S.
Lupascu, A.
Nista, E. C.
Cremonini, F.
Bartolozzi, F.
Gasbarrini, A.
Ojetti, V.
Cammarota, G.
Author_xml – sequence: 1
  givenname: S.
  surname: Di Caro
  fullname: Di Caro, S.
– sequence: 2
  givenname: V.
  surname: Ojetti
  fullname: Ojetti, V.
– sequence: 3
  givenname: M. A.
  surname: Zocco
  fullname: Zocco, M. A.
– sequence: 4
  givenname: F.
  surname: Cremonini
  fullname: Cremonini, F.
– sequence: 5
  givenname: F.
  surname: Bartolozzi
  fullname: Bartolozzi, F.
– sequence: 6
  givenname: M.
  surname: Candelli
  fullname: Candelli, M.
– sequence: 7
  givenname: A.
  surname: Lupascu
  fullname: Lupascu, A.
– sequence: 8
  givenname: E. C.
  surname: Nista
  fullname: Nista, E. C.
– sequence: 9
  givenname: G.
  surname: Cammarota
  fullname: Cammarota, G.
– sequence: 10
  givenname: A.
  surname: Gasbarrini
  fullname: Gasbarrini, A.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13822716$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11876707$$D View this record in MEDLINE/PubMed
BookMark eNqNkE1OwzAQhS0Eoi1wBeQNOxLGduykCxYI8SeBYAESO8t2bOEqjSO7iHbHETgjJyGhFd2ymtG890ZP3wTttqG1CGECOYFCnM1ywgTPKDCRUwCaAyGC58sdNP4TdtEYqJhmtCJshCYpzQBAlED30YiQquzXcoxeH0IbTnH9rhqs2hovou8ai-dh6V0Tlsr49vvzS6tke-3NRtV5m7ALEd_axpuglVnYiLtVE6LHvV57oxY-tIdoz6km2aPNPEAv11fPl7fZ_ePN3eXFfWY4ITwrjJ1SXlhaTjlY0ELwglAQrJoypyxw5ZhxhWCgGadO16UmWitRacWF6e8HqFr_NTGkFK2TXfRzFVeSgBxgyZkcmMiBiRxgyV9YctlHj9fR7l3Pbb0Nbuj0hpONQSWjGhdVa3za-lhFaUmGDudr34dv7OrfBeTF0_OwsR_c3YhS
CitedBy_id crossref_primary_10_1046_j_1523_5378_7_s1_7_x
crossref_primary_10_1111_j_1523_5378_2011_00826_x
crossref_primary_10_1111_j_1523_5378_2011_00867_x
crossref_primary_10_1046_j_0954_6820_2003_01239_x
crossref_primary_10_1111_j_1523_5378_2007_00548_x
crossref_primary_10_1016_S0210_5705_03_70366_5
crossref_primary_10_1111_j_1523_5378_2007_00588_x
crossref_primary_10_1007_s00508_008_1122_2
crossref_primary_10_1089_jwh_2012_4171
crossref_primary_10_1007_s00508_007_0807_2
crossref_primary_10_1586_14787210_1_3_363
crossref_primary_10_5009_gnl14020
crossref_primary_10_1517_13543784_15_9_995
crossref_primary_10_1046_j_1365_2036_2003_01592_x
crossref_primary_10_5114_amscd_2018_78766
crossref_primary_10_1016_j_ejmhg_2013_03_004
crossref_primary_10_1111_j_0083_8703_2006_00371_x
crossref_primary_10_1038_ncpgasthep0288
crossref_primary_10_3109_1061186X_2016_1171326
crossref_primary_10_1517_13543776_16_8_1107
crossref_primary_10_2169_internalmedicine_48_2344
crossref_primary_10_1111_j_1083_4389_2004_00220_x
crossref_primary_10_1016_j_dld_2009_05_013
crossref_primary_10_3748_wjg_v26_i15_1733
crossref_primary_10_1046_j_1365_2036_2003_01566_x
crossref_primary_10_1111_j_1523_5378_2007_00535_x
crossref_primary_10_1111_1751_2980_12171
crossref_primary_10_1517_14656566_3_9_1301
crossref_primary_10_1016_j_carbpol_2015_10_052
crossref_primary_10_1517_13543776_14_10_1453
crossref_primary_10_1097_00004836_200402000_00005
crossref_primary_10_1111_j_1365_2036_2005_02412_x
crossref_primary_10_1039_C8NJ05480K
crossref_primary_10_1007_s10620_008_0285_z
crossref_primary_10_1177_1756283X10384171
crossref_primary_10_1016_S0210_5705_03_70485_3
crossref_primary_10_3748_wjg_v21_i18_5568
Cites_doi 10.1136/gut.45.2008.i9
10.3109/00365529609094548
10.1136/gut.45.2008.i40
10.1046/j.1365-2036.2000.00685.x
10.1046/j.1365-2036.2000.00846.x
10.1046/j.1365-2036.2000.00788.x
10.1111/j.1572-0241.2000.01836.x
10.1093/jac/46.2.283
10.1046/j.1365-2036.2001.00971.x
10.1111/j.1348-0421.2000.tb01240.x
10.1016/S0149-2918(00)80053-3
10.2165/00002018-199920020-00008
10.2165/00003495-199958002-00013
10.1517/14656566.2.2.317
10.1592/phco.20.4.245.34880
10.2174/0929867013373435
10.2165/00003495-199754030-00010
10.1046/j.1440-1746.2000.02262.x
10.1080/00365540050164272
10.1111/j.1742-1241.2000.tb11913.x
10.2165/00003495-199957030-00007
10.1179/joc.2000.12.2.129
10.1016/S0149-2918(00)80032-6
10.2165/00003495-199958002-00012
10.1128/AAC.43.10.2345
10.1093/jac/43.suppl_2.91
10.1016/S0887-2333(00)00017-5
10.1128/AAC.43.11.2793
10.1016/S0016-5085(98)70100-3
10.1046/j.1365-2036.2000.00719.x
10.2165/00003495-200059010-00010
10.1097/00042737-199409000-00004
10.1136/gut.41.1.8
10.1016/S0924-8579(99)00143-0
10.1016/S1590-8658(00)80282-0
10.1093/jac/43.suppl_2.43
10.1046/j.1365-2036.2000.00675.x
10.1046/j.1365-2036.2001.00909.x
10.2165/00002018-200022060-00006
10.1046/j.1365-2036.1999.00555.x
10.1097/00004836-200010000-00007
10.1136/gut.43.2008.S47
ContentType Journal Article
Copyright 2002 INIST-CNRS
Copyright_xml – notice: 2002 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1046/j.1365-2036.2002.01165.x
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2036
EndPage 532
ExternalDocumentID 10_1046_j_1365_2036_2002_01165_x
11876707
13822716
APT1165
Genre article
Comparative Study
Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EST
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TR2
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YOC
ZZTAW
~IA
~WT
AAJUZ
AAVGM
ABCVL
ABHUG
ABPTK
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c5115-4ce9254e27950e0b665412063893fae05af3cf4630b352fbd7b1bba68ba56c463
IEDL.DBID DR2
ISSN 0269-2813
IngestDate Fri Aug 23 03:20:02 EDT 2024
Sat Sep 28 08:39:07 EDT 2024
Sun Oct 22 16:08:52 EDT 2023
Sat Aug 24 00:59:36 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Human
Drug combination
Clarithromycin
Spirillales
Toxicity
Spirillaceae
Moxifloxacin
Eradication
Macrolide
Biological activity
Chemotherapy
Fluoroquinolone derivatives
Randomization
Treatment
Helicobacter pylori
Benzimidazole derivatives
Antisecretory agent
Bacteria
Drug interaction
Antibacterial agent
Lansoprazole
Quinolone derivatives
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5115-4ce9254e27950e0b665412063893fae05af3cf4630b352fbd7b1bba68ba56c463
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2002.01165.x
PMID 11876707
PageCount 6
ParticipantIDs crossref_primary_10_1046_j_1365_2036_2002_01165_x
pubmed_primary_11876707
pascalfrancis_primary_13822716
wiley_primary_10_1046_j_1365_2036_2002_01165_x_APT1165
PublicationCentury 2000
PublicationDate March 2002
PublicationDateYYYYMMDD 2002-03-01
PublicationDate_xml – month: 03
  year: 2002
  text: March 2002
PublicationDecade 2000
PublicationPlace Oxford UK
PublicationPlace_xml – name: Oxford UK
– name: Oxford
– name: England
PublicationTitle Alimentary pharmacology & therapeutics
PublicationTitleAlternate Aliment Pharmacol Ther
PublicationYear 2002
Publisher Blackwell Science Ltd
Blackwell
Publisher_xml – name: Blackwell Science Ltd
– name: Blackwell
References 1997; 41
2000; 46
2000; 22
2000; 44
2000; 20
2000; 95
1999; 45
1999; 43
1999; 20
1998; 115
2000; 1
1998; 43
2000; 19
2000; 14
2000; 59
1997; 54
2000; 15
2000; 12
2000; 54
2000; 32
2000; 31
1999; 58
2001; 8
1999; 13
1999; 57
2001; 15
2001; 2
1998; 30
1996; 8
1994; 6
1996; 215
e_1_2_6_30_2
e_1_2_6_18_2
e_1_2_6_19_2
e_1_2_6_12_2
e_1_2_6_35_2
e_1_2_6_13_2
e_1_2_6_34_2
e_1_2_6_33_2
e_1_2_6_11_2
e_1_2_6_32_2
e_1_2_6_16_2
e_1_2_6_39_2
e_1_2_6_17_2
e_1_2_6_38_2
e_1_2_6_14_2
e_1_2_6_37_2
e_1_2_6_15_2
Gasbarrini G (e_1_2_6_36_2) 1998; 30
e_1_2_6_42_2
e_1_2_6_20_2
e_1_2_6_41_2
e_1_2_6_40_2
Muloler M (e_1_2_6_23_2) 1999; 43
DeBoer WA (e_1_2_6_31_2) 1996; 8
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_29_2
e_1_2_6_4_2
e_1_2_6_3_2
Pestova E (e_1_2_6_45_2) 2000; 19
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_24_2
e_1_2_6_47_2
e_1_2_6_2_2
e_1_2_6_22_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_43_2
Ball P. (e_1_2_6_10_2) 2000; 54
e_1_2_6_27_2
e_1_2_6_44_2
Barrett JF. (e_1_2_6_9_2) 2000; 1
e_1_2_6_26_2
e_1_2_6_25_2
e_1_2_6_46_2
References_xml – volume: 8
  start-page: 371
  year: 2001
  end-page: 84
  article-title: Adverse reactions to fluoroquinolones, an overview on mechanistic aspects
  publication-title: Curr Med Chem
– volume: 2
  start-page: 317
  year: 2001
  end-page: 35
  article-title: Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features
  publication-title: Expert Opin Pharmacother
– volume: 30
  start-page: S244
  year: 1998
  end-page: 7
  article-title: New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report
  publication-title: Ital J Gastroenterol Hepatol
– volume: 58
  start-page: 65
  year: 1999
  end-page: 70
  article-title: Effect of quinolones on intestinal ecology
  publication-title: Drugs
– volume: 6
  start-page: 773
  year: 1994
  end-page: 7
  article-title: Short‐term low‐dose therapy for the eradication of Helicobacter pylori
  publication-title: Eur J Gastroenterol Hepatol
– volume: 14
  start-page: 7
  year: 2000
  end-page: 14
  article-title: Nitroimidazole resistance in
  publication-title: Aliment Pharmacol Ther
– volume: 32
  start-page: 81
  year: 2000
  end-page: 5
  article-title: Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora
  publication-title: Scand J Infect Dis
– volume: 45
  start-page: I9
  year: 1999
  end-page: 12
  article-title: Extradigestive manifestations of Helicobacter pylori gastric infection
  publication-title: Gut
– volume: 41
  start-page: 8
  year: 1997
  end-page: 13
  article-title: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
  publication-title: Gut
– volume: 8
  start-page: 641
  year: 1996
  end-page: 3
  article-title: Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens
  publication-title: Eur J Gastroenterol Hepatol
– volume: 22
  start-page: 479
  year: 2000
  end-page: 85
  article-title: Fluoroquinolones‐induced renal failure
  publication-title: Drug Safety
– volume: 31
  start-page: 222
  year: 2000
  end-page: 5
  article-title: Rifabutin‐based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience
  publication-title: J Clin Gastroenterol
– volume: 95
  start-page: 646
  year: 2000
  end-page: 50
  article-title: Validation of the 13C‐urea breath test for the diagnosis of Helicobacter pylori infection in children: a multicenter study
  publication-title: Am J Gastroenterol
– volume: 59
  start-page: 115
  year: 2000
  end-page: 39
  article-title: Moxifloxacin: a review of its clinical potential in the management of community‐acquired respiratory tract infections
  publication-title: Drugs
– volume: 14
  start-page: 275
  year: 2000
  end-page: 83
  article-title: Comparison of an in vitro cellular phototoxicity model against controlled clinical trials of fluoroquinolone skin phototoxicity
  publication-title: Toxicol In Vitro
– volume: 57
  start-page: 363
  year: 1999
  end-page: 73
  article-title: Moxifloxacin
  publication-title: Drugs
– volume: 1
  start-page: 45
  year: 2000
  end-page: 51
  article-title: Moxifloxacin Bayer
  publication-title: Curr Opin Invest Drugs
– volume: 43
  start-page: 2345
  year: 1999
  end-page: 9
  article-title: Penetration of moxifloxacin into peripheral compartments in humans
  publication-title: Antimicrob Agents Chemother
– volume: 43
  start-page: 91
  year: 1999
  end-page: 100
  article-title: Preclinical evaluation of moxifloxacin, a novel fluoroquinolone
  publication-title: J Antimicrob Chemother
– volume: 58
  start-page: 60
  year: 1999
  end-page: 4
  article-title: Quinolone activity against anaerobes
  publication-title: Drugs
– volume: 43
  start-page: S47
  year: 1998
  end-page: 50
  article-title: Urea breath tests in the management of Helicobacter pylori infection
  publication-title: Gut
– volume: 46
  start-page: 283
  year: 2000
  end-page: 5
  article-title: Susceptibility of Helicobacter pylori to mupirocin, oxazolidones, quinupristin/dalfopristin and new quinolones
  publication-title: J Antimicrob Chemother
– volume: 44
  start-page: 9
  year: 2000
  end-page: 15
  article-title: Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu‐Chu‐Yu), against Helicobacter pylori in vitro
  publication-title: Microbiol Immunol
– volume: 45
  start-page: I40
  year: 1999
  end-page: 4
  article-title: Treatment failure: the problem of non‐responders
  publication-title: Gut
– volume: 22
  start-page: 266
  year: 2000
  end-page: 80
  article-title: The proton pump inhibitors: similarities and differences
  publication-title: Clin Ther
– volume: 22
  start-page: 798
  year: 2000
  end-page: 817
  article-title: The safety profile of the fluoroquinolones
  publication-title: Clin Ther
– volume: 15
  start-page: 707
  year: 2001
  end-page: 13
  article-title: The impact of resistance to clarithromycin on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy
  publication-title: Aliment Pharmacol Ther
– volume: 215
  start-page: 118
  year: 1996
  end-page: 118
  article-title: Italian omeprazole triple therapy: a 1 week regimen
  publication-title: Scand J Gastroenterol Suppl
– volume: 32
  start-page: S214
  year: 2000
  end-page: 6.
  article-title: Helicobacter pylori‐related extradigestive diseases and effects of eradication therapy
  publication-title: Dig Liver Dis
– volume: 12
  start-page: 129
  year: 2000
  end-page: 33
  article-title: Effects of subinhibitory concentrations of moxifloxacin in an in‐vitro dynamic model
  publication-title: J Chemother
– volume: 54
  start-page: 473
  year: 1997
  end-page: 500
  article-title: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid‐related disorders
  publication-title: Drugs
– volume: 14
  start-page: 311
  year: 2000
  end-page: 6
  article-title: Rifabutin‐based rescue therapy for infected patients after failure of standard regimens
  publication-title: Aliment Pharmacol Ther
– volume: 19
  start-page: 228
  year: 2000
  end-page: 32
  article-title: Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones
  publication-title: J Antimicrob Chemother
– volume: 13
  start-page: 1047
  year: 1999
  end-page: 55
  article-title: A systematic review of eradication therapy. The impact of antimicrobial resistance on eradication rates
  publication-title: Aliment Pharmacol Ther
– volume: 14
  start-page: 45
  year: 2000
  end-page: 50
  article-title: Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram‐negative and Gram‐positive organisms
  publication-title: Int J Antimicrob Agents
– volume: 43
  start-page: 2793
  year: 1999
  end-page: 7
  article-title: Pharmacokinetics of once‐daily oral dose of moxifloxacin (Bay 12‐8039), a new enantiomerically pure 8‐methoxy quinolone
  publication-title: Antimicrob Agents Chemother
– volume: 54
  start-page: 329
  year: 2000
  end-page: 32
  article-title: Moxifloxacin: an 8‐methoxyquinolone antibacterial with enhanced potency
  publication-title: Int J Clin Pract
– volume: 20
  start-page: 195
  year: 1999
  end-page: 205
  article-title: Safety profile of lansoprazole: the US clinical trial experience
  publication-title: Drug Safety
– volume: 14
  start-page: 1339
  year: 2000
  end-page: 43
  article-title: Efficacy of two one‐week rabeprazole/levofloxacin‐based triple therapies for infection
  publication-title: Aliment Pharmacol Ther
– volume: 20
  start-page: 245
  year: 2000
  end-page: 56
  article-title: Moxifloxacin, a new antibiotic designed to treat community‐acquired respiratory tract infections: a review of microbiologic and pharmacokinetic–pharmacody namic characteristics
  publication-title: Pharmacotherapy
– volume: 14
  start-page: 963
  year: 2000
  end-page: 78
  article-title: Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
  publication-title: Aliment Pharmacol Ther
– volume: 15
  start-page: G30
  year: 2000
  end-page: 3
  article-title: Helicobacter pylori: past, present and future
  publication-title: J Gastroenterol Hepatol
– volume: 115
  start-page: 1272
  year: 1998
  end-page: 7
  article-title: Antibiotic resistance in Helicobacter pylori: implications for therapy
  publication-title: Gastroenterology
– volume: 43
  start-page: 43
  year: 1999
  end-page: 9
  article-title: Bactericidal properties of moxifloxacin and post‐antibiotic effect
  publication-title: J Antimicrob Chemother
– volume: 14
  start-page: 79
  year: 2000
  end-page: 83
  article-title: Efficacy of a multistep strategy for eradication
  publication-title: Aliment Pharmacol Ther
– volume: 15
  start-page: 143
  year: 2001
  end-page: 143
  article-title: Letter to editors: Rifabutin‐based eradication rescue therapy
  publication-title: Aliment Pharmacol Ther
– ident: e_1_2_6_34_2
  doi: 10.1136/gut.45.2008.i9
– ident: e_1_2_6_38_2
  doi: 10.3109/00365529609094548
– ident: e_1_2_6_40_2
  doi: 10.1136/gut.45.2008.i40
– ident: e_1_2_6_42_2
  doi: 10.1046/j.1365-2036.2000.00685.x
– ident: e_1_2_6_7_2
  doi: 10.1046/j.1365-2036.2000.00846.x
– ident: e_1_2_6_26_2
  doi: 10.1046/j.1365-2036.2000.00788.x
– ident: e_1_2_6_29_2
  doi: 10.1111/j.1572-0241.2000.01836.x
– ident: e_1_2_6_44_2
  doi: 10.1093/jac/46.2.283
– ident: e_1_2_6_41_2
  doi: 10.1046/j.1365-2036.2001.00971.x
– volume: 1
  start-page: 45
  year: 2000
  ident: e_1_2_6_9_2
  article-title: Moxifloxacin Bayer
  publication-title: Curr Opin Invest Drugs
  contributor:
    fullname: Barrett JF.
– volume: 8
  start-page: 641
  year: 1996
  ident: e_1_2_6_31_2
  article-title: Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens
  publication-title: Eur J Gastroenterol Hepatol
  contributor:
    fullname: DeBoer WA
– ident: e_1_2_6_43_2
  doi: 10.1111/j.1348-0421.2000.tb01240.x
– ident: e_1_2_6_13_2
  doi: 10.1016/S0149-2918(00)80053-3
– ident: e_1_2_6_27_2
  doi: 10.2165/00002018-199920020-00008
– ident: e_1_2_6_20_2
  doi: 10.2165/00003495-199958002-00013
– ident: e_1_2_6_24_2
  doi: 10.1517/14656566.2.2.317
– ident: e_1_2_6_11_2
  doi: 10.1592/phco.20.4.245.34880
– ident: e_1_2_6_18_2
  doi: 10.2174/0929867013373435
– ident: e_1_2_6_28_2
  doi: 10.2165/00003495-199754030-00010
– ident: e_1_2_6_32_2
  doi: 10.1046/j.1440-1746.2000.02262.x
– ident: e_1_2_6_19_2
  doi: 10.1080/00365540050164272
– volume: 54
  start-page: 329
  year: 2000
  ident: e_1_2_6_10_2
  article-title: Moxifloxacin: an 8‐methoxyquinolone antibacterial with enhanced potency
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2000.tb11913.x
  contributor:
    fullname: Ball P.
– ident: e_1_2_6_22_2
  doi: 10.2165/00003495-199957030-00007
– ident: e_1_2_6_46_2
  doi: 10.1179/joc.2000.12.2.129
– ident: e_1_2_6_25_2
  doi: 10.1016/S0149-2918(00)80032-6
– ident: e_1_2_6_14_2
  doi: 10.2165/00003495-199958002-00012
– volume: 43
  start-page: 2345
  year: 1999
  ident: e_1_2_6_23_2
  article-title: Penetration of moxifloxacin into peripheral compartments in humans
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.43.10.2345
  contributor:
    fullname: Muloler M
– ident: e_1_2_6_8_2
  doi: 10.1093/jac/43.suppl_2.91
– ident: e_1_2_6_17_2
  doi: 10.1016/S0887-2333(00)00017-5
– ident: e_1_2_6_21_2
  doi: 10.1128/AAC.43.11.2793
– ident: e_1_2_6_37_2
  doi: 10.1016/S0016-5085(98)70100-3
– ident: e_1_2_6_5_2
  doi: 10.1046/j.1365-2036.2000.00719.x
– ident: e_1_2_6_12_2
  doi: 10.2165/00003495-200059010-00010
– ident: e_1_2_6_2_2
  doi: 10.1097/00042737-199409000-00004
– ident: e_1_2_6_35_2
  doi: 10.1136/gut.41.1.8
– volume: 19
  start-page: 228
  year: 2000
  ident: e_1_2_6_45_2
  article-title: Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones
  publication-title: J Antimicrob Chemother
  contributor:
    fullname: Pestova E
– ident: e_1_2_6_15_2
  doi: 10.1016/S0924-8579(99)00143-0
– ident: e_1_2_6_33_2
  doi: 10.1016/S1590-8658(00)80282-0
– ident: e_1_2_6_47_2
  doi: 10.1093/jac/43.suppl_2.43
– volume: 30
  start-page: S244
  year: 1998
  ident: e_1_2_6_36_2
  article-title: New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report
  publication-title: Ital J Gastroenterol Hepatol
  contributor:
    fullname: Gasbarrini G
– ident: e_1_2_6_39_2
  doi: 10.1046/j.1365-2036.2000.00675.x
– ident: e_1_2_6_6_2
  doi: 10.1046/j.1365-2036.2001.00909.x
– ident: e_1_2_6_16_2
  doi: 10.2165/00002018-200022060-00006
– ident: e_1_2_6_3_2
  doi: 10.1046/j.1365-2036.1999.00555.x
– ident: e_1_2_6_4_2
  doi: 10.1097/00004836-200010000-00007
– ident: e_1_2_6_30_2
  doi: 10.1136/gut.43.2008.S47
SSID ssj0006702
Score 1.9436978
Snippet Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections....
Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. To compare the...
SourceID crossref
pubmed
pascalfrancis
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 527
SubjectTerms 2-Pyridinylmethylsulfinylbenzimidazoles
Adolescent
Adult
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Aza Compounds
Biological and medical sciences
Clarithromycin - adverse effects
Clarithromycin - therapeutic use
Drug Combinations
Female
Fluoroquinolones
Helicobacter Infections - drug therapy
Helicobacter pylori
Humans
Lansoprazole
Male
Medical sciences
Middle Aged
Moxifloxacin
Omeprazole - adverse effects
Omeprazole - analogs & derivatives
Omeprazole - therapeutic use
Patient Compliance
Pharmacology. Drug treatments
Quinolines
Treatment Outcome
Title Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication
URI https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2036.2002.01165.x
https://www.ncbi.nlm.nih.gov/pubmed/11876707
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7Sgwji-1EfJQeP7pJ9ZvdYxFKEikgLvS1JNoFS3ZbaQvHkT_A3-kucyW5tKx5EvC2bZJdkJpkvycw3hFzJRKQqZcqJmOJOiG6uguXG0VwwrQzPc8vA17mP273wrh_1K_8njIUp-SG-DtxwZtj1Gie4kGUWEmbZbRceWrAEW08D1zLJuIgnkVcP8dHjkkkq5tb9EHYcqeMnXlA59VQXnD9-aM1SbY_FCwyaKbNdrJirVUhrbVJrlwwXvSldUYbubCpd9fqN6PF_urtHdiroSpulru2TDV0ckM1OdTl_SPqwPoyuKQZ3UVHkdDrBQ3z6PJoPzNNoLqDWx9s7mk0os2FfsEunAJop2D5QSGmJo-kYjxAGFMrz6jzxiPRat92btlMlbnAU4LfICZVOYeOpfZ5GTDOJGY49vwRHRmgWCRMoE8YBk4D_jMy59KQUcSJFFCt4f0xqxajQp4RCtVQBJAl5osMg0XhtG3mBNDkz2uNenXgLIWXjkp8js_fqIcag4ZBlOGSYbdPP7JBl8zpprElz2RD0xocNZJ2clOJdlnhgNTjjdRJbIf36X1nzoYtPZ39teE62bAIa6_Z2QWrTyUxfAg6ayobV8E_FfPls
link.rule.ids 315,786,790,1382,27955,27956,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEB5EQQXx_ajPHDy6Ndt9ZPdYfFAfFZEKvS1JNgFR26IViid_gr_RX-JMdmtVPIh4WzbJLpnJZL7MTGYAdlUiU51y7UVcCy-kMFfJc-sZIbnRVuS5y8DXvIgb1-FpO2qX5YDoLkyRH-LD4EaS4fZrEnAySO-XbslCyl2IFu7BLtSg6lLJVBFQTqD0RySlh1ejXFKxcAGIeOZIvVriB2VYT-ni_PFLX3TVTE8-ItlsUe_ik8L6DGqdVjqeg7vhfIpglNvqU19V9fO3VI__NOF5mC3RK6sXy20BxkxnESabpX9-Cdq4RXT3GN3vYrKTs_4D2fHZfXdwY--6A4m93l5eSXNim7v5hQd1hriZofrDNalc7mjWIyvCDcP2vDQpLsP18VHroOGVtRs8jRAu8kJtUjx7mppII264oiLHfq3AR1YaHkkbaBvGAVcIAa3KhfKVknGiZBRrfL8C451ux6wBw26pRlQSisSEQWLIcxv5gbI5t8YXfgX8IZeyXpGiI3Ou9ZCuoRHJMiIZFdysZY5k2aAC21_YORoYIGLCM2QFVgv-jlp8VByCiwrEjku__ldWv2zR0_pfB-7AVKPVPM_OTy7ONmDa1aNxUXCbMN5_eDJbCIv6atst93d_V_2M
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEB6kQhHE96M-c_Do1uwzu8eilvoqIhZ6W5JsAkXdFm2hePIn-Bv9JU6yq63iQcTbskl2yUyS-eaRGYADEfNEJlQ6IZXMCUyYK6eZdhTjVEnNssxm4LtqR61OcN4Nu2X8k7kLU-SH-DS4mZ1hz2uzwQeZPiq9ksUmtxFaeATbSIO6zSRTRzw5G0S-ZxSxk5tJKqmI2fhDVDkSx4tdv4zqKT2cP37pi6iaH_AnpJouyl1MyatpTGuFUnMR7j6mU8Si3NVHQ1GXz98yPf7PfJdgocSupFEstmWYUfkKVK9K7_wqdPGA6B8Sc7uL8Dwjw0djxScP_XFP3_fHHHu9vbwauYlt9t4XqukEUTNB4YcrUtjM0WRgbAg9gu1ZaVBcg07z9Pa45ZSVGxyJAC50AqkS1DyVx5KQKipMiWPXK9CR5oqGXPtSI5uoQACoRcaEKwSPYsHDSOL7dajk_VxtAsFuiURMErBYBX6sjN82dH2hM6qVy9wauB9MSgdFgo7UOtYDcwnNkCw1JDPlNr3Ukiwd12DvCzcnA33ES6hB1mCjYO-kxUWxwSirQWSZ9Ot_pY3rW_O09deB-1C9Pmmml2fti22Ys8VobAjcDlSGjyO1i5hoKPbsYn8HeaX8Ow
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mono%2C+dual+and+triple+moxifloxacin%E2%80%90based+therapies+for+Helicobacter+pylori+eradication&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Di+Caro%2C+S.&rft.au=Ojetti%2C+V.&rft.au=Zocco%2C+M.+A.&rft.au=Cremonini%2C+F.&rft.date=2002-03-01&rft.pub=Blackwell+Science+Ltd&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=16&rft.issue=3&rft.spage=527&rft.epage=532&rft_id=info:doi/10.1046%2Fj.1365-2036.2002.01165.x&rft.externalDBID=10.1046%252Fj.1365-2036.2002.01165.x&rft.externalDocID=APT1165
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon